Cambridge, Massachusetts, United States, February 2026 – Johnson & Johnson Innovative Medicine has appointed Kristin Schuhwerk as SVP, Head of Global Development, marking a significant leadership step in advancing the organization’s global development strategy.
Kristin steps into the role after serving as SVP, Global Head, R&D Strategy, Portfolio & Operations at Johnson & Johnson Innovative Medicine, where she led enterprise-wide R&D planning, portfolio governance, and operational excellence initiatives. Her expanded mandate now places her at the helm of Global Development, overseeing the progression of innovative therapies from clinical strategy through execution.
Prior to joining Johnson & Johnson, Kristin served as Chief Operating Officer at Scorpion Therapeutics, where she drove operational strategy in a precision oncology-focused biotech environment. She also held multiple senior leadership roles at Sanofi, including VP, Global Head of Project & Portfolio Management, Development, VP, Global Head Clinical Operations, and leadership positions within Oncology R&D Operations. Her experience further includes a leadership role at Moderna Therapeutics as VP, Head of Therapeutic Operations, along with earlier positions at Novelos Therapeutics, Antigenics, Brigham & Women’s Hospital – TIMI Study Group, and Astra Pharmaceuticals.
In addition to her executive roles, Kristin serves as Board Director at The START Center for Cancer Research, reflecting her continued engagement in advancing oncology research and clinical innovation.
With deep expertise across clinical development, R&D operations, portfolio strategy, and global execution, Kristin brings more than two decades of experience in guiding complex development programs. Her appointment reinforces Johnson & Johnson Innovative Medicine’s commitment to science-driven innovation and patient-centered advancement.
About Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine focuses on advancing science-based innovations to address some of the world’s most complex diseases. Guided by patient experiences and powered by rigorous research, the organization develops transformative medicines aimed at improving and saving lives globally. Through its commitment to innovation, compassion, and scientific excellence, Johnson & Johnson Innovative Medicine continues to pioneer progress from lab to life.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
